<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2958548-A1" country="EP" doc-number="2958548" kind="A1" date="20151230" family-id="49223837" file-reference-id="301920" date-produced="20180822" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="160454130" ucid="EP-2958548-A1"><document-id><country>EP</country><doc-number>2958548</doc-number><kind>A1</kind><date>20151230</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-14705166-A" is-representative="NO"><document-id mxw-id="PAPP193871228" load-source="patent-office" format="original"><country>EP</country><doc-number>14705166.8</doc-number><date>20140218</date><lang>EN</lang></document-id><document-id mxw-id="PAPP193871229" load-source="docdb" format="epo"><country>EP</country><doc-number>14705166</doc-number><kind>A</kind><date>20140218</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC162033492" ucid="EP-2014053109-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>2014053109</doc-number><kind>W</kind><date>20140218</date></document-id></priority-claim><priority-claim mxw-id="PPC162034757" ucid="TR-201301951-A" load-source="docdb"><document-id format="epo"><country>TR</country><doc-number>201301951</doc-number><kind>A</kind><date>20130219</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1988524053" load-source="docdb">A61K  31/64        20060101ALI20140912BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988525067" load-source="docdb">A61K   9/00        20060101AFI20140912BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988525153" load-source="docdb">A61P   3/10        20060101ALI20140912BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1987773899" load-source="docdb" scheme="CPC">A61K  31/64        20130101 LI20131118BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987782490" load-source="docdb" scheme="CPC">A61K   9/1652      20130101 LA20141014BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987790005" load-source="docdb" scheme="CPC">A61K   9/2054      20130101 LA20141014BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987792532" load-source="docdb" scheme="CPC">A61K   9/1694      20130101 FI20141014BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987794427" load-source="docdb" scheme="CPC">A61K   9/1611      20130101 LA20141014BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT165553856" lang="DE" load-source="patent-office">VERFAHREN ZUR HERSTELLUNG VON GLICLAZID-FORMULIERUNGEN</invention-title><invention-title mxw-id="PT165553857" lang="EN" load-source="patent-office">A PRODUCTION PROCESS FOR GLICLAZIDE FORMULATIONS</invention-title><invention-title mxw-id="PT165553858" lang="FR" load-source="patent-office">PROCÉDÉ DE PRODUCTION DE FORMULATIONS DE GLICLAZIDE</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR1103303838" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>SANOVEL ILAC SANAYI VE TICARET AS</last-name><address><country>TR</country></address></addressbook></applicant><applicant mxw-id="PPAR1103340032" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>SANOVEL ILAC SANAYI VE TICARET A.S.</last-name></addressbook></applicant><applicant mxw-id="PPAR1101649971" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Sanovel Ilac Sanayi ve Ticaret A.S.</last-name><iid>101336570</iid><address><street>Balabandere Cad. Ilac Sanayi Yolu No: 14 Istinye</street><city>34460 Istanbul</city><country>TR</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR1103307177" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>TÜRKYILMAZ ALI</last-name><address><country>TR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103332412" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>TÜRKYILMAZ, Ali</last-name></addressbook></inventor><inventor mxw-id="PPAR1101649025" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>TÜRKYILMAZ, Ali</last-name><address><street>SANOVEL Ilac Sanayi ve Ticaret A.S. Balabandere Cad. Ilac Sanayi Yolu No: 14 Istinye</street><city>34460 Istanbul</city><country>TR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103337807" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>PEHLIVAN AKALIN NUR</last-name><address><country>TR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103330776" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>PEHLIVAN AKALIN, Nur</last-name></addressbook></inventor><inventor mxw-id="PPAR1101651859" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>PEHLIVAN AKALIN, Nur</last-name><address><street>SANOVEL Ilac Sanayi ve Ticaret A.S. Balabandere Cad. Ilac Sanayi Yolu No: 14 Istinye</street><city>34460 Istanbul</city><country>TR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103312642" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>SUCUOGLU ESRA</last-name><address><country>TR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103306960" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>Sucuoglu, Esra</last-name></addressbook></inventor><inventor mxw-id="PPAR1101650639" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>Sucuoglu, Esra</last-name><address><street>SANOVEL Ilac Sanayi ve Ticaret A.S. Balabandere Cad. Ilac Sanayi Yolu No: 14 Istinye</street><city>34460 Istanbul</city><country>TR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103324833" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>HATIRNAZ ZEKIYE BASAK</last-name><address><country>TR</country></address></addressbook></inventor><inventor mxw-id="PPAR1103303319" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>HATIRNAZ, Zekiye Basak</last-name></addressbook></inventor><inventor mxw-id="PPAR1101646442" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>HATIRNAZ, Zekiye Basak</last-name><address><street>SANOVEL Ilac Sanayi ve Ticaret A.S. Balabandere Cad. Ilac Sanayi Yolu No: 14 Istinye</street><city>34460 Istanbul</city><country>TR</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR1101650097" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Sevinç, Erkan</last-name><iid>100731001</iid><address><street>Istanbul Patent A.S. Plaza-33, Büyükdere Cad. No: 33/16 Sisli</street><city>34381 Istanbul</city><country>TR</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="EP-2014053109-W"><document-id><country>EP</country><doc-number>2014053109</doc-number><kind>W</kind><date>20140218</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2014128116-A1"><document-id><country>WO</country><doc-number>2014128116</doc-number><kind>A1</kind><date>20140828</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS660796691" load-source="docdb">AL</country><country mxw-id="DS660729727" load-source="docdb">AT</country><country mxw-id="DS660796693" load-source="docdb">BE</country><country mxw-id="DS660646402" load-source="docdb">BG</country><country mxw-id="DS660649051" load-source="docdb">CH</country><country mxw-id="DS660741913" load-source="docdb">CY</country><country mxw-id="DS660729728" load-source="docdb">CZ</country><country mxw-id="DS660796694" load-source="docdb">DE</country><country mxw-id="DS660741914" load-source="docdb">DK</country><country mxw-id="DS660741935" load-source="docdb">EE</country><country mxw-id="DS660731180" load-source="docdb">ES</country><country mxw-id="DS660646407" load-source="docdb">FI</country><country mxw-id="DS660646408" load-source="docdb">FR</country><country mxw-id="DS660796695" load-source="docdb">GB</country><country mxw-id="DS660741936" load-source="docdb">GR</country><country mxw-id="DS660796696" load-source="docdb">HR</country><country mxw-id="DS660729729" load-source="docdb">HU</country><country mxw-id="DS660649052" load-source="docdb">IE</country><country mxw-id="DS660796697" load-source="docdb">IS</country><country mxw-id="DS660646409" load-source="docdb">IT</country><country mxw-id="DS660741937" load-source="docdb">LI</country><country mxw-id="DS660652098" load-source="docdb">LT</country><country mxw-id="DS660729730" load-source="docdb">LU</country><country mxw-id="DS660652107" load-source="docdb">LV</country><country mxw-id="DS660652108" load-source="docdb">MC</country><country mxw-id="DS660765819" load-source="docdb">MK</country><country mxw-id="DS660765820" load-source="docdb">MT</country><country mxw-id="DS660646410" load-source="docdb">NL</country><country mxw-id="DS660731181" load-source="docdb">NO</country><country mxw-id="DS660649053" load-source="docdb">PL</country><country mxw-id="DS660765821" load-source="docdb">PT</country><country mxw-id="DS660646415" load-source="docdb">RO</country><country mxw-id="DS660765822" load-source="docdb">RS</country><country mxw-id="DS660646416" load-source="docdb">SE</country><country mxw-id="DS660765827" load-source="docdb">SI</country><country mxw-id="DS660731182" load-source="docdb">SK</country><country mxw-id="DS660649054" load-source="docdb">SM</country><country mxw-id="DS660652110" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA139078755" ref-ucid="WO-2014128116-A1" lang="EN" load-source="patent-office"><p num="0000">A process for producing a gliclazide formulation comprising impurity B in an amount not exceeding 3 ppm, characterized in that a temperature not higher than 60°C is applied in any of the production steps of this formulation.</p></abstract><abstract mxw-id="PA139545310" ref-ucid="WO-2014128116-A1" lang="EN" source="national office" load-source="docdb"><p>A process for producing a gliclazide formulation comprising impurity B in an amount not exceeding 3 ppm, characterized in that a temperature not higher than 60°C is applied in any of the production steps of this formulation.</p></abstract><abstract mxw-id="PA139078756" ref-ucid="WO-2014128116-A1" lang="FR" load-source="patent-office"><p num="0000">Procédé de production d'une formulation de gliclazide comprenant une impureté B dans une quantité ne dépassant pas 3 ppm, caractérisé en ce qu'une température non supérieure à 60 °C est appliquée à l'une quelconque des étapes de production de cette formulation.</p></abstract><abstract mxw-id="PA139545311" ref-ucid="WO-2014128116-A1" lang="FR" source="national office" load-source="docdb"><p>Procédé de production d'une formulation de gliclazide comprenant une impureté B dans une quantité ne dépassant pas 3 ppm, caractérisé en ce qu'une température non supérieure à 60 °C est appliquée à l'une quelconque des étapes de production de cette formulation.</p></abstract><description mxw-id="PDES78477686" ref-ucid="WO-2014128116-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> A PRODUCTION PROCESS FOR GLICLAZIDE FORMULATIONS </p><p id="p0002" num="0002">Field of Invention The present invention relates to improving the stability of formulations comprising gliclazide. The present invention more particularly relates to a process for producing stable gliclazide formulations comprising an impurity in a pharmaceutically acceptable level. Background of Invention </p><p id="p0003" num="0003">Diabetes mellitus is an abnormality of the glucose metabolism, which occurs due to causes like insufficient insulin secretion and decreased sensitivity of target cells to insulin and is characterized by hyperglycemia. In persistent hyperglycemia, severe harmful complications such as retinopathy, nephropathy, and neuropathy occur as a result of vascular lesions in various organs and nerves. </p><p id="p0004" num="0004">Many anti-diabetic medicaments, including sulfonylureas, have been administered orally in the treatment of diabetics so far. </p><p id="p0005" num="0005">Sulfonylurea is a name defining a group of orally administered anti-diabetic medicaments used in the treatment of type II diabetes mellitus. Diabetes mellitus is a disorder of the carbohydrate metabolism, in which insulin secretion is diminished, or which occurs due to a varying insulation secretion or decreased insulin activity or a combination of both factors. It is believed that sulfonylureas stimulate the insulin secretion from pancreatic islet cells in the mediation of receptors which were reported as adenosine 5'-triphosphate-sensitive potassium channels (KATP). For this reason, sulfonylureas basically increase the endogenous insulin secretion so that an efficient control is provided in the blood sugar levels, not controllable via diets, of the diabetics and particularly of the type II diabetics. </p><p id="p0006" num="0006">Sulfonylureas are considered to be divided into two categories: first generation agents, e.g. tolbutamide, chlorpropamide, tolazamide, acetohexamide; and second generation agents, e.g. glyburide (glibenclamide), glipizide, gliclazide. 
<!-- EPO <DP n="3"/>-->
 Gliclazide N-(4-methylbenzenesulfonyl)-N'-(3-azabicyclo[3.3.0]-oct-3-yl)urea), one type of second generation sulfonylureas, is an active agent with antidiabetic properties at typical doses administered to humans (its chemical structure is illustrated in Formula 1 )- </p><p id="p0007" num="0007"><img id="imgf000003_0001" he="22" wi="70" file="imgf000003_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0008" num="0008"> H </p><p id="p0009" num="0009">Formula 1 </p><p id="p0010" num="0010">Gliclazide has been administered in the form of 30, 60, 80 mg tablets until today. It is usually administrated twice a day, making a total of two tablets per day. It may be altered, however, to 1 - 4 tablets per day, as required by the severity of the diabetes case. 30 mg and 60 mg modified-release dosage forms are also available at the markets. The formulation of gliclazide, which is the active agent, was first disclosed on 10.12.1996 with the patent document US 3,501 ,495 (SCIENCE UNION ET CIE. SOC), disclosing the formula N-(4-methylbenzenesulphonyl)-N'-(3-azabicyclo[3.3.0]-oct-3- yl)urea), which has hypoglycemic properties and is orally administered in the treatment of diabetes mellitus. </p><p id="p0011" num="0011">Gliclazide formulations were disclosed in many different patents in the past. </p><p id="p0012" num="0012">The patent US 4,696,815 discloses immediate-release tablets comprising sulfonylurea, formulated using an acidified and/or alkalized excipient and an inert polar solvent like polyethylene glycol. An analogous immediate-release formulation comprising an acidified and/or alkalized excipient, an inert polar solvent, and polyvinylpyrrolidone is also described in that patent. </p><p id="p0013" num="0013">The patent US 6,733,782 discloses a core tablet for the controlled-release of gliclazide, ensuring a sustained and constant release of the active agent by making use of hydroxypropylmethyl cellulose (HPMC) which is not influenced from the pH variations of the solubilizing medium following oral administration. The main target of that 
<!-- EPO <DP n="4"/>-->
 invention is to obtain an oral dosage form, which can be administered once a day and provides extended release. That US patent provides information on using a glucose syrup, e.g. maltodextrin, together with cellulosic polymers in order to obtain a controlled and full release from a gliclazide formulation. </p><p id="p0014" num="0014">The patent document WO2008/062470, in turn, relates to a stabilized controlled release dosage form of gliclazide, having one or more release controlling polymer, calcium hydrogen phosphate anhydrous and free from saccharide component. It is further stated in that patent document that calcium hydrogen phosphate dihydrate is the reason for the high impurity A. </p><p id="p0015" num="0015">After gliclazide formulations are formulated, the formation of various impurities and particularly of impurity B are observed. Obtaining gliclazide formulations using processes involving heat leads to impurities of various types. Having said that, the poor water-solubility of gliclazide is another problem. In order to achieve desirable release profiles, those processes involving heat, such as wet granulation and hot melting method, are preferred. These preferences, in turn, make it necessary to apply heat during the process and drying steps. Heat application, however, particularly results in the formation of 2-nitroso-octahydrocyclopenta[c]pyrrole, i.e. the impurity B. This, in turn, is unfavorable in terms of pharmaceutics. Therefore, a special formulation and process embodiment is needed that would overcome this problem. </p><p id="p0016" num="0016">Description of Invention The present invention provides a gliclazide formulation, eliminating all aforesaid problems and bringing additional advantages to the relevant prior art. </p><p id="p0017" num="0017">Accordingly, the main object of the present invention is to obtain a gliclazide formulation, which is stable, comprises an impurity in a pharmaceutically acceptable level, and has a desirable level of solubility and dissolution rate. </p><p id="p0018" num="0018">Another object of the present invention is to obtain a controlled-release formulation comprising impurity B in a pharmaceutically acceptable level. A further object of the present invention is to obtain a stable controlled-release formulation having high bioavailability. 
<!-- EPO <DP n="5"/>-->
 A production process for a gliclazide formulation comprising not more than 3 ppm impurity B has been developed to carry out all objects, referred to above and to emerge from the following detailed description. </p><p id="p0019" num="0019">According to a preferred embodiment of the present invention, said novelty is characterized in that the formulation is exposed to heat at a temperature not higher than 60 'Ό during any of the productions steps. According to a preferred embodiment of the present invention, the formulation is exposed to heat preferably at a temperature not higher than δΟ 'Ό, and more preferably at a temperature between 40 - 45^ during any of the productions steps. </p><p id="p0020" num="0020">According to a preferred embodiment of the present invention, said process is a wet granulation process or a hot melting process. </p><p id="p0021" num="0021">According to a preferred embodiment of the present invention, heat is applied during the granulation phase or the drying phase of granules of the wet granulation process. According to a preferred embodiment of the present invention, heat is applied during the melting phase of the hot melting process. </p><p id="p0022" num="0022">According to a preferred embodiment of the present invention, the formulation is in the form of a solid formulation, liquid formulation, or a gel formulation. </p><p id="p0023" num="0023">According to a preferred embodiment of the present invention, the formulation is in the form of a controlled-release solid formulation or an immediate-release solid formulation. </p><p id="p0024" num="0024">According to a preferred embodiment of the present invention, the formulation is in the form of a 30 mg, 60 mg, or 80 mg dosage form. </p><p id="p0025" num="0025">According to a preferred embodiment of the present invention, the solid dosage form does not have a breaking notch, a breaking surface or a breaking line. According to a preferred embodiment of the present invention, the d<sub>90</sub> particle size of gliclazide is 75 μηι. 
<!-- EPO <DP n="6"/>-->
 According to a preferred embodiment of the present invention, the d<sub>5</sub>o particle size of gliclazide is 20 μηι. </p><p id="p0026" num="0026">According to a preferred embodiment of the present invention, the di<sub>0</sub> particle size of gliclazide is 5 μηι. </p><p id="p0027" num="0027"> According to a preferred embodiment of the present invention, the formulation comprises a polymer which controls the release rate. </p><p id="p0028" num="0028">According to a preferred embodiment of the present invention, the polymer that controls the release rate is selected from a group consisting of hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), ethyl cellulose (EC), methyl cellulose (MC), sodium carboxymethyl cellulose, and cellulose acetate butyrate, or a mixture thereof. According to a preferred embodiment of the present invention, the polymer that controls the release rate is hydroxypropyl methylcellulose. </p><p id="p0029" num="0029">According to a preferred embodiment of the present invention, the viscosity of the hydroxypropyl methylcellulose polymer that controls the release rate is 100 cP. </p><p id="p0030" num="0030">According to a preferred embodiment of the present invention, the viscosity of the hydroxypropyl methylcellulose polymer that controls the release rate is 4000 cP. </p><p id="p0031" num="0031">According to a preferred embodiment according to the present invention, the viscosity of hydroxypropyl methylcellulose present in the internal phase is 4000 cP. </p><p id="p0032" num="0032">According to a preferred embodiment of the present invention, the total amount of the polymer that controls the release rate is between 10 and 30% of the tablet weight. Another preferred embodiment according to the present invention further comprises at least one or a mixture of fillers, glidants, and lubricants as an excipient. </p><p id="p0033" num="0033">According to another preferred embodiment of the present invention, said filler comprises at least one or a mixture of calcium hydrogen phosphate dihydrate, calcium hydrogen phosphate anhydrous, and mannitol. 
<!-- EPO <DP n="7"/>-->
 According to another preferred embodiment of the present invention, said glidant is colloidal silicon dioxide. </p><p id="p0034" num="0034">According to another preferred embodiment of the present invention, said lubricant magnesium stearate. </p><p id="p0035" num="0035">According to a further preferred embodiment of to the present invention, said formulation comprises the following ingredients only: </p><p id="p0036" num="0036"> 15 - 22% by weight of gliclazide, </p><p id="p0037" num="0037"> 1 .8 - 3.0% by weight of hydroxypropyl methylcellulose 4000 cP, 12 - 25% by weight of calcium hydrogen phosphate dihydrate, iv. 7.5 - 9.0% by weight of hydroxypropyl methylcellulose 100 cP, v. 55 - 80% by weight of mannitol, </p><p id="p0038" num="0038"> vi. 0.05 - 0.5% by weight of colloidal silicon dioxide, </p><p id="p0039" num="0039"> vii. 0.25 - 1 .0% by weigh of magnesium stearate. </p><p id="p0040" num="0040">Example </p><p id="p0041" num="0041"> A controlled-release pharmaceutical tablet formulation of gliclazide </p><p id="p0042" num="0042">This example describes a controlled-release pharmaceutical tablet formulation comprising gliclazide or a pharmaceutically-acceptable salt thereof. The active ingredient and excipients of the tablet are given below: </p><p id="p0043" num="0043">Controlled-release tablet formulation </p><p id="p0044" num="0044">Example 1 </p><p id="p0045" num="0045"> Amount, % </p><p id="p0046" num="0046"> Gliclazide 15 - 22 </p><p id="p0047" num="0047"> Hydroxypropyl methylcellulose 4000 cP 1 .8 - 3.0 </p><p id="p0048" num="0048"> Calcium hydrogen phosphate dihydrate 12 - 25 </p><p id="p0049" num="0049"> Hydroxypropyl methylcellulose 100 cP 7.5 - 9.0 </p><p id="p0050" num="0050"> Mannitol 35 - 55 </p><p id="p0051" num="0051"> Colloidal silicon dioxide 0.05 - 0.5 </p><p id="p0052" num="0052"> Magnesium stearate 0.25 - 1 .0 
<!-- EPO <DP n="8"/>-->
 Gliclazide, calcium hydrogen phosphate dihydrate, mannitol, and some part of hydroxypropyl methylcellulose (4000 cP) (E4M) are mixed together in a granulator. Water is sprayed onto the resulting mixture and is thus granulated. </p><p id="p0053" num="0053">5 The wet granules prepared are directly transferred to a fluidized bed dryer. The granules are dried in the fluidized bed dryer until the humidity thereof is reduced to 1 % or below, and dried granules are sieved and passed to a mixer. </p><p id="p0054" num="0054">The remaining part of hydroxypropyl methylcellulose (E4M), the entire amount of 10 hydroxypropyl methylcellulose (K100LV), and colloidal silicon dioxide are added to the sieved dry granules and mixed together. Then, magnesium stearate is added to the resulting mixture and mixing is continued. The mixture is compressed into tablets. </p><p id="p0055" num="0055">Example </p><p id="p0056" num="0056"> 15 60 mq controlled-release tablet/capsule </p><p id="p0057" num="0057"><img id="imgf000008_0001" he="58" wi="107" file="imgf000008_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0058" num="0058">Gliclazide, calcium hydrogen phosphate dihydrate, mannitol, and some part of hydroxypropyl methylcellulose (4000 cP) (E4M) are mixed together in a granulator. 20 Water is sprayed onto the resulting mixture and is thus granulated. d<sub>90</sub>, d<sub>50</sub>, and di<sub>0</sub> particle sizes of gliclazide are 75 μηι, 20 μηι, and 5 μηι, respectively. </p><p id="p0059" num="0059">The wet granules prepared are directly transferred to a fluidized bed dryer. Here, heat is applied at a temperature not higher than 60 °C, preferably not more than 50 'C, and more</p><p id="p0060" num="0060">25 preferably at a temperature between 40-45^. 
<!-- EPO <DP n="9"/>-->
 The granules are dried in the fluidized bed dryer until the humidity thereof is reduced to 1 % or below, preferably 0.7% or below, and dried granules are sieved and passed to a mixer. The remaining part of hydroxypropyl methylcellulose (E4M), the entire amount of hydroxypropyl methylcellulose (K100LV), and colloidal silicon dioxide are added to the sieved dry granules and mixed together. Then, magnesium stearate is added to the resulting mixture and mixing is continued. The mixture is filled into capsules or compressed into tablets. </p><p id="p0061" num="0061">Surprisingly, a gliclazide formulation is obtained with the present invention, showing improved stability and comprising impurity B in a pharmaceutically acceptable amount, not more than 3 ppm. The formulation according to the present invention may be in the form of a solid, liquid, or gel. It was determined that the temperature applied during the solving, drying, and similar phases of the wet granulation process or during the hot melting process had a direct influence of the formation of the B-type impurity. However, in order to provide acceptable levels of solubility and dissolution rate, the active agents should be dissolved under the influence of temperature. Accordingly, the present invention provides a heterogeneous matrix, which comprises active agent particles, at least some part thereof being dissolved under heat and the remaining part thereof left undissolved, by virtue of a formulation having a balanced content. In obtaining the heterogeneous matrix, the particle size of the active agent and the influence of temperature are directly effective. In wet granulation, a heterogeneous matrix is obtained in which not more than 20% of gliclazide is completely dissolved, and the remaining part thereof is left undissolved in a particulate form. Accordingly, by virtue of the preferred particle size and the maximum heat/temperature values applied during the production process, such formulations can be obtained according to the present invention, which comprise a pharmaceutically acceptable amount of impurity and show a desirable dissolution rate and solubility. For instance, a controlled-release formulation can be obtained as mentioned above. It is further possible to easily carry out a conventional tablet production. </p><p id="p0062" num="0062">Additionally, using mannitol in the formulation according to the present invention is effective in preventing the formation of impurity B. The ratio of mannitol in the total formulation is above 55% and it can prevent the formation of impurity in an amount above 55%. 
<!-- EPO <DP n="10"/>-->
 When the formulation comprises mannitol more than 55% and a temperature is applied in any of the production steps of this formulation which is not more than 60 'C, preferably not more than 50 'C, and more preferably between 40-45 °C, the amount of impurity B 5 drops down below 3 ppm and is observed at around 0.7 ppm. </p><p id="p0063" num="0063">The impurity B of the formulation is determined by HPLC (High-Performance Liquid Chromatography). </p><p id="p0064" num="0064">10 Chromatographic conditions; </p><p id="p0065" num="0065"> - Column : Chromolith RP-18e, 100 x 4.60 mm </p><p id="p0066" num="0066"> - Flow rate : 1 .2 mlJ min </p><p id="p0067" num="0067"> - Detection wavelength : UV, 230 nm </p><p id="p0068" num="0068"> - Injection volume : 100 μ\- 15 - Column temperature : 50 ^ </p><p id="p0069" num="0069"> - Tray temperature : 15 'C </p><p id="p0070" num="0070"> - Analyzing time : 30 minutes </p><p id="p0071" num="0071"> Mobile Phase= Buffer : Acetonitrile : Tetrahydrofuran (80 : 17 : 3), (h / h / h) </p><p id="p0072" num="0072"> The pH of the buffer: 6.00 </p><p id="p0073" num="0073"> 20 </p><p id="p0074" num="0074"> A desirable dissolution profile and dissolution rate can be achieved using hydroxypropyl methylcellulose E4M and hydroxypropyl methylcellulose K100LV, when gliclazide with a d<sub>90</sub> particle size of 75 μηι, a d<sub>50</sub> particle size of 20 μηι, and a di<sub>0</sub> particle size of 5 μηι is used and a temperature is applied in any of the production steps which is not more than 25 60 'C, preferably not more than 50 °C, and more preferably in between 40-45^. </p><p id="p0075" num="0075">In this invention, the particle size of the active agent is measured by MALVERN MASTERSIZER 2000 by using dry dispersion method. </p><p id="p0076" num="0076"> Optical properties: </p><p id="p0077" num="0077">30 - Particle refractive index : 1 .5 </p><p id="p0078" num="0078"> - Absorption : 0 </p><p id="p0079" num="0079"> - Calculation model : General Purpose </p><p id="p0080" num="0080"> - Background time : 6 sec </p><p id="p0081" num="0081"> - Measurement time : 6 sec </p><p id="p0082" num="0082">35 - Vibration rate : % 40 </p><p id="p0083" num="0083"> - Air pressure : 2.5 bar 
<!-- EPO <DP n="11"/>-->
 The process according to the present invention makes it possible to obtain a 30 mg controlled-release tablet formulation. </p><p id="p0084" num="0084">The process according to the present invention makes it possible to obtain a 60 mg controlled-release tablet formulation. </p><p id="p0085" num="0085">The process according to the present invention makes it possible to obtain a 80 mg controlled-release tablet formulation. This formulation is used for preventing or treating diabetes mellitus in mammalians, particularly in humans. </p><p id="p0086" num="0086">It is also possible to use the terms "modified-release", "extended-release", "prolonged- release", and "sustained-release" in place of the term "controlled-release". </p><p id="p0087" num="0087">Polymers can be used to form a matrix in which the active agent is dispersed. The release rate of the active agent depends on the properties of the polymer used. The cellulose derivates thereof are particularly hydroxypropyl methylcellulose (HPMC) and hydroxypropyl cellulose (HPC), see "Handbook of Pharmaceutical Excipients (Ed. A Wade and P. J. Weller, Pharmaceutical Press, London 1994). The properties of a polymer when it contacts an aqueous medium and particularly a physiological medium can be used for controlling the release rate of an active agent from a controlled-release formulation. For instance, polymers like HPMC frequently develop a gel-like outer layer that is dissolved or worn away and thus control the permeation of water into the interior of the controlled-release formulation. It is known that the release of an active agent from such controlled-release formulations is controlled by a combination of many factors, including the properties of the active agent, the diffusion properties of the active agent or of the solution in which it is just dissolved, the penetration rate of water into the interior of the polymer matrix, swelling features of the polymer matrix, and the dissolution rate of the gel layer of the outer polymer. </p><p id="p0088" num="0088">The present invention makes use of mannitol as a binder and a hydrophilic diluent with a low glycemic index. A preferred embodiment of this invention is a controlled-release pharmaceutical tablet formulation, comprising (a) a therapeutically-effective amount of gliclazide or a 
<!-- EPO <DP n="12"/>-->
 pharmaceutically-acceptable salt thereof, (b) mannitol as a binder and hydrophilic diluent, not increasing the blood glucose level in human patients who are in the need of a non-insulin dependent diabetes mellitus (NIDDM) treatment, (c) calcium hydrogen phosphate dihydrate or calcium hydrogen phosphate anhydrous as a diluent, (d) two different types of pharmaceutically-acceptable cellulosic polymers as a release rate- controlling polymer, wherein not more than 25% of the total amount of gliclazide or a pharmaceutically-acceptable salt thereof is dissolved in a shorter time than two hours and wherein the blood glucose level is not increased. The pharmaceutically-acceptable cellulosic polymer controlling the release rate include, but is not limited to HPMC, HPC, hydroxyethyl cellulose (HEC), ethyl cellulose (EC), methyl cellulose (MC), sodium carboxymethyl cellulose and cellulose acetate butyrate or a mixture thereof. The preferred polymer according to the present invention is HPMC, used as a release rate-controlling polymer. According to a most preferred embodiment, the viscosity of HPMC is 1 00 cP and 4000 cP. </p><p id="p0089" num="0089">The amount of the release rate-controlling polymer is 10 - 30%, the amount of calcium hydrogen phosphate dihydrate or calcium hydrogen phosphate anhydrous is 12 - 25%, and the amount of mannitol is above 55% in the controlled-release pharmaceutical tablet formulation according to the present invention. </p><p id="p0090" num="0090">According to another preferred embodiment of the present invention, the controlled- release pharmaceutical tablet formulation further comprises at least one excipient. This excipient is selected from a group consisting of glidants and lubricants. </p><p id="p0091" num="0091">As indicated above, the glidant may be selected from a group consisting of colloidal silicon dioxide, silica, calcium silicate, magnesium trisilicate, sodium stearyl fumarate, talk, etc.. The glidant is preferably colloidal silicon dioxide used in an amount of 0.05 - 0.5%. </p><p id="p0092" num="0092">As indicated above, the lubricant is selected from a group consisting of magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oils, vegetable-derived fatty acids, etc.. The lubricant is preferably magnesium stearate used in an amount of 0.25 - 1 .0% 
<!-- EPO <DP n="13"/>-->
 In a most preferred embodiment of the controlled-release pharmaceutical tablet formulation according to the present invention, conducting an in vitro dissolution test using a USP paddle method in a 900 ml medium (0.05 M pH 7.5 phosphate buffer) at 75 rpm and 37°C should provide a dissolution rate for calcium hydrogen phosphate dihydrate or calcium hydrogen phosphate anhydrous and mannitol, together with HPMC, gliclazide or a pharmaceutically-acceptable salt thereof not more than 25% in 2 hours, 30 - 65% in 6 hours, and not less than 85% in 24 hours. As indicated above, the cellulosic polymer is hydroxypropyl methylcellulose 100 cP or 4000 cP used in an amount of 10 - 30%, the amount of calcium hydrogen phosphate dihydrate or calcium hydrogen phosphate anhydrous is 12 - 25% and the amount of mannitol is above 55%. The problems related to the prior art are solved with the present invention and the objects referred to hereinabove of this invention are achieved with a novel controlled- release pharmaceutical tablet formulation. </p><p id="p0093" num="0093">The present invention is hereby disclosed by referring to exemplary embodiments hereinabove. These exemplary embodiments do not restrict the object of the present invention and must be evaluated under the light of the foregoing detailed description. 
</p></description><claims mxw-id="PCLM70077966" ref-ucid="WO-2014128116-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="14"/>-->CLAIMS </claim-statement><claim id="clm-0001" num="1"><claim-text>1 . A process for producing a gliclazide formulation comprising impurity B in an amount not exceeding 3 ppm, characterized in that a temperature not higher than 60°C is applied in any of the production steps of this formulation. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. The process according to Claim 1 , wherein a temperature preferably not higher than 50 °C and more preferably a temperature between 40 - 45 °C is applied in any of the productions steps of this formulation. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. The process according to any of the preceding claims, wherein this process is a wet granulation process or a hot melting process. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. The process according to any of the preceding claims, wherein the specified temperatures are applied during the granulation step or during the granule drying step of the wet granulation process. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. The process according to any of the preceding claims, wherein the specified temperatures are applied during the melting step the hot melting process. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. A formulation produced by means of a process according to any of the preceding claims, wherein this formulation is in the form of a solid, liquid, or a gel. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. The formulation produced by means of a process according to any of the preceding claims, wherein this formulation is in the form of a controlled-release solid formulation or an immediate-release solid formulation. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. The formulation produced by means of a process according to any of the preceding claims, wherein this formulation is in the form of a controlled-release solid formulation or an immediate-release solid formulation. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. The formulation produced by means of a process according to any of the preceding claims, wherein this formulation is a 30 mg, 60 mg, or 80 mg dosage formulation. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. The formulation produced by means of a process according to any of the preceding claims, wherein the solid dosage form does not comprise a breaking notch, a breaking surface or a breaking line. 
<!-- EPO <DP n="15"/>-->
</claim-text></claim><claim id="clm-0011" num="11"><claim-text>1 1 . The formulation produced by means of a process according to any of the preceding claims, wherein the d<sub>90</sub> particle size of gliclazide is 75 μηι. </claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. The formulation produced by means of a process according to any of the preceding claims, wherein the d<sub>5</sub>o particle size of gliclazide is 20 μηι. </claim-text></claim><claim id="clm-0013" num="13"><claim-text>1 3. The formulation produced by means of a process according to any of the preceding claims, wherein the di<sub>0</sub> particle size of gliclazide is 5 μηι. </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. The formulation produced by means of a process according to any of the preceding claims, wherein the formulation comprises a release rate-controlling polymer. </claim-text></claim><claim id="clm-0015" num="15"><claim-text>15. The formulation produced by means of a process according to any of the preceding claims, wherein the release rate-controlling polymer is selected from a group consisting of hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), ethyl cellulose (EC), methyl cellulose (MC), sodium carboxymethyl cellulose and cellulose acetate butyrate, or a mixture thereof. </claim-text></claim><claim id="clm-0016" num="16"><claim-text>1 6. The formulation produced by means of a process according to any of the preceding claims, wherein the release rate-controlling polymer is hydroxypropyl methylcellulose. </claim-text></claim><claim id="clm-0017" num="17"><claim-text>17. The formulation produced by means of a process according to any of the preceding claims, wherein the viscosity of hydroxypropyl methylcellulose as the release rate- controlling polymer is 100 cP. </claim-text></claim><claim id="clm-0018" num="18"><claim-text>18. The formulation produced by means of a process according to any of the preceding claims, wherein the viscosity of hydroxypropyl methylcellulose as the release rate- controlling polymer is 4000 cP. </claim-text></claim><claim id="clm-0019" num="19"><claim-text>1 9. The formulation produced by means of a process according to any of the preceding claims, wherein the amount of the release rate-controlling polymer is between 10- 30%. 
<!-- EPO <DP n="16"/>-->
</claim-text></claim><claim id="clm-0020" num="20"><claim-text>20. The formulation produced by means of a process according to any of the preceding claims, wherein this formulation comprises at least one or a mixture of fillers, glidants, and lubricants as excipient. </claim-text></claim><claim id="clm-0021" num="21"><claim-text>21 . The formulation produced by means of a process according to any of the preceding claims, this formulation further comprising mannitol. </claim-text></claim><claim id="clm-0022" num="22"><claim-text>22. The formulation produced by means of a process according to any of the preceding claims, comprising the following ingredients only: </claim-text><claim-text> 15 - 22% by weight of gliclazide, </claim-text><claim-text> 1 .8 - 3.0% by weight of hydroxypropyl methylcellulose 4000 cP, </claim-text><claim-text> 12 - 25% by weight of calcium hydrogen phosphate dihydrate, iv. 7.5 - 9.0% by weight of hydroxypropyl methylcellulose 100 cP, v. 55 - 80% by weight of mannitol, </claim-text><claim-text> vi. 0.05 - 0.5% by weight of colloidal silicon dioxide, </claim-text><claim-text> vii. 0.25 - 1 .0% by weigh of magnesium stearate. </claim-text></claim><claim id="clm-0023" num="23"><claim-text>23. The formulation produced by means of a process according to any of the preceding claims for preventing or treating diabetes mellitus in mammalians, particularly in humans. 
</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
